Novartis CEO Shrugs Off Paltry Price For Flu Vaccines Unit
This article was originally published in PharmAsia News
Executive Summary
Novartis says the $275 million received from Australia’s CSL for its influenza unit was not a great price but was “the best” on offer, allowing the Swiss group to fully exit vaccines and continue moving ahead on its strategic plan.